Cognitive Function and Statin Administration During Doxorubicin-Based Cancer Treatment

A secondary analysis of the PREVENT trial led by Dr. W. Gregory Hundley highlights that cancer patients undergoing anthracycline treatment who receive atorvastatin may not suffer cognitive decline. The study evaluated 238 patients with lymphoma or breast cancer and found no significant differences in cognitive function between those taking statins and placebo over 24 months. Notably, atorvastatin users showed improved executive function scores, suggesting possible cognitive benefits, challenging previous notions of statins negatively impacting cognition in cancer treatments.